Evidence map›Paper›PMID 34980800›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Successful Treatment of Antibody-mediated Pure Red Cell Aplasia Induced by Continuous Erythropoietin Receptor Activator with Prednisolone.

Nozomi Okahashi, Masayuki Kubo, Ei Hoshino, Masahito Uchihara, Itsuto Amano, Haruyuki Tanaka

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nozomi OkahashiDepartment of Internal Medicine, Saiseikai Chuwa Hospital, Japan.
Masayuki KuboDepartment of Hematology, Nara Medical University, Japan.
Ei HoshinoDepartment of Internal Medicine, Saiseikai Chuwa Hospital, Japan.
Masahito UchiharaDepartment of Internal Medicine, Saiseikai Chuwa Hospital, Japan.
Itsuto AmanoDepartment of Hematology, Nara Medical University, Japan.
Haruyuki TanakaDepartment of Hematology, Nara Medical University, Japan.
Jikei University Kashiwa hospital · JPNara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pure red cell aplasia (PRCA) associated with erythropoiesis-stimulating agents (ESAs), which were first reported in 1998, usually occurs with subcutaneous administration of epoetin alfa (Eprex

Indexed as

AnemiaHematinicsRed-Cell Aplasia, PureAntibodiesEpoetin AlfaErythropoietinHumansPolyethylene GlycolsPrednisoloneRecombinant ProteinsAntibodiescontinuous erythropoietin receptor activatorEpoetin AlfaErythropoietinHematinicsPolyethylene GlycolsPrednisoloneRecombinant Proteinsantibody-mediated pure red cell aplasiaanti-CERA antibodyanti-erythropoietin antibodycontinuous erythropoietin receptor activatorerythropoiesis-stimulating agents

Identifiers

PMID34980800
PMCPMC9381349
OpenAlexW4200555232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.